A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109)

Efficacy of pemetrexed and carboplatin with or without bevacizumab in lung adenocarcinoma patients with EGFR non‐T790M mutations after progression on first‐line EGFR‐tyrosine kinase inhibitors

“…More importantly, PFS (8.2 months), OS (26.3 months), and ORR (46.7%) were improved when bevacizumab was added to chemotherapy in our study. A similar study in Japan also reported that PC + B achieved a PFS of 6.6 months and an ORR of 37% in patients who had experienced failure of first‐line EGFR‐TKIs . Another study showed that a bevacizumab plus pemetrexed regimen was superior to pemetrexed monotherapy, even as third‐line therapy in patients with EGFR mutated lung adenocarcinoma (median OS 38.76 vs. 36.22 months, respectively; P = 0.04) .…”

“…A similar study in Japan also reported that PC + B achieved a PFS of 6.6 months and an ORR of 37% in patients who had experienced failure of first-line EGFR-TKIs. 13 Another study showed that a bevacizumab plus pemetrexed regimen was superior to pemetrexed monotherapy, even as third-line therapy in patients with EGFR mutated lung adenocarcinoma (median OS 38.76 vs. 36.22 months, respectively; P = 0.04). 14 In addition, in animal experiments, Furugaki et al confirmed that bevacizumab could enhance antitumor activity in T790M negative rather than in T790M positive tumors.…”

Effect of miR-1244 on cisplatin-treated non-small cell lung cancer via MEF2D expression

“…In recent years, NSCLC has exhibited a rising morbidity rate. Furthermore, the pathogenesis of NSCLC has not been established (17,18). Currently, it is believed that cell cycle control abnormalities are associated with the cancerous transformation of cells; malignant tumors may have a dysregulated cell cycle (17).…”

“…Furthermore, the pathogenesis of NSCLC has not been established (17,18). Currently, it is believed that cell cycle control abnormalities are associated with the cancerous transformation of cells; malignant tumors may have a dysregulated cell cycle (17). In the present study, we observed that the expression levels of miR-1244 in the cisplatin-treated A549 and NCI-H522 cells were lower than those of the untreated A549 and NCI-H522 cells, and that the OS time of the cisplatin-treated NSCLC patients with high miR-1244 expression was greater than the patients with low miR-1244 expression.…”

Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations

“…Bai et al [20] also showed that chemotherapy may reduce the EGFR-mutation frequency in both plasma and tumor tissue, and accordingly suspected a reduction in the overall clinical benefit of subsequent EGFR-TKI treatment after chemotherapy. One recent study reported that platinum-based chemotherapy after initial gefitinib achieved a low response of only 7 % [13], whereas other studies have documented the effectiveness of cytotoxic agents after EGFR-TKIs against NSCLC with EGFR mutations [21][22][23]. Conversely, Deng et al [24] used the lung adenocarcinoma cell lines PC9 and PC9/G, which have acquired resistance to gefitinib, to explore the influence of acquired resistance of EGFR-TKIs on the sensitivity of tumor cells to chemotherapeutic drugs, and showed no significant differences between these two cell lines, and several other studies have suggested that prior EGFR-TKI therapy does not influence the efficacy of subsequent platinum combination chemotherapy in NSCLC patients harboring sensitive EGFR mutations [14,22].…”